Alimera’s Iluvien Fails to Win Backing From U.K. Cost AgencyMakiko Kitamura
Alimera Sciences Inc. failed to win the backing of the U.K.’s health-cost agency for its treatment for the leading cause of blindness associated with diabetes.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.